<?xml version="1.0" encoding="UTF-8"?>
<p>AZM is rapidly absorbed after oral administration with a large volume of distribution
 <xref rid="rmv2163-bib-0109" ref-type="ref">
  <sup>109</sup>
 </xref> and a long serum half‐life of approximately 3 days,
 <xref rid="rmv2163-bib-0110" ref-type="ref">
  <sup>110</sup>
 </xref> leading to a high and sustained tissue concentration. A striking feature of macrolides is that they can accumulate in host cells including epithelial cells and most particularly in phagocytes where they may concentrate 100‐ to 3000‐fold in the lysosomes of phagocytes,
 <xref rid="rmv2163-bib-0077" ref-type="ref">
  <sup>77</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0081" ref-type="ref">
  <sup>81</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0111" ref-type="ref">
  <sup>111</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0112" ref-type="ref">
  <sup>112</sup>
 </xref> being subsequently retained intracellularly
 <xref rid="rmv2163-bib-0078" ref-type="ref">
  <sup>78</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0080" ref-type="ref">
  <sup>80</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0081" ref-type="ref">
  <sup>81</sup>
 </xref> and released when these cells die. Therefore typical AZM concentrations after one‐three 500 mg oral doses may be 0.29 μM (0.22 mg/L) in plasma, but 12 μM in lung tissue homogenate, 48 μM in bronchial washings and 260 μM in alveolar macrophages.
 <xref rid="rmv2163-bib-0113" ref-type="ref">
  <sup>113</sup>
 </xref> Several studies have observed initial stimulatory effects of AZM on immune and epithelial cells. Acutely, AZM stimulates neutrophil degranulation and phagocytosis‐associated oxidative burst, mediated via modulation of Erk1/2 signalling.
 <xref rid="rmv2163-bib-0079" ref-type="ref">
  <sup>79</sup>
 </xref> These initial stimulatory effects are followed by modulation of transcription factors activator protein (AP)‐1, nuclear factor kappa B (NFκB), inflammatory cytokine and mucin release, with overall anti‐inflammatory effects.
</p>
